How Semax Influences Gene Expression in Experimental Models of Brain Ischemia

Introduction
In a genome-wide transcriptional study conducted by Medvedeva et al. (2014), the synthetic peptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was investigated to better understand its molecular effects in the context of focal cerebral ischemia in rats. Although Semax has been used as a neuroprotective agent in stroke therapy, the researchers noted that the precise biological processes it influences at the gene expression level remained unclear before this study.
Study Objective
The primary objective of the research by Medvedeva and colleagues was to examine how Semax influences global gene expression patterns in ischemized brain tissue. Specifically, the researchers aimed to identify which genes exhibited altered expression in the rat cerebral cortex following permanent middle cerebral artery occlusion (pMCAO) and to understand the biological processes affected by the peptide.
Methods
According to the methods described by Medvedeva et al., adult rats underwent permanent occlusion of the middle cerebral artery to model focal ischemic injury. The animals were then treated with Semax, and cortical tissue samples were collected at 3 and 24 hours after ischemia onset. Gene expression levels in the Semax-treated group were compared to those in an ischemia-only control group using genome-wide expression profiling with a RatRef-12 Expression BeadChip array, which contains over 22,000 genes. The researchers used a cut-off criterion of 1.50-fold change to determine significantly altered gene expression.
Findings
Medvedeva and colleagues reported that Semax administration led to extensive changes in gene expression in ischemic brain cortex tissue. At 3 hours after ischemia onset, 96 genes showed altered expression relative to untreated ischemic controls, with both increased and decreased expression patterns observed. By 24 hours, 68 genes were differentially expressed, with the majority showing increased expression. The researchers found that genes related to the immune response represented a large proportion of the altered gene set. Specifically, Semax modulated expression of multiple immunoglobulin and chemokine-related genes, suggesting enhanced immune-related activity following peptide treatment. Additionally, Semax influenced the expression of genes associated with vascular processes, including those involved in endothelial development, smooth muscle migration, hematopoiesis, and vasculogenesis, at both time points.
The study concluded that the peptide’s most pronounced transcriptional effects under ischemic conditions were related to immune system activation and vascular processes. Medvedeva et al. suggested that these gene expression changes may underlie the neuroprotective and functional effects previously observed with Semax treatment, though further research would be needed to directly link specific transcriptional changes to physiological outcomes.

Important Notice
This content is provided for educational and informational purposes only. The research discussed relates exclusively to laboratory and scientific investigation. No claims are made regarding biological activity, therapeutic use, or outcomes. Compounds referenced are not intended for human or veterinary use.

Sources
Medvedeva E. V. et al. (2014). The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics (PMC).